• There are no suggestions because the search field is empty.

ICP-MS vs ICP-OES analysis: choosing the right elemental impurity testing method

Author Avatar
Yves Peeraer, Division Head Lab Services at QbD Group
Lab Services
Pharma & Biotech
Learn the differences between ICP-MS and ICP-OES for elemental impurity testing. Compare sensitivity, cost, and regulatory compliance to make the best choice. 
ICP-MS vs ICP-OES: choosing the right elemental impurity test
4:51

 

Elemental impurities in medicinal products and excipients are a major concern for regulatory authorities. The ICH Q3D guidelines set clear expectations for controlling these impurities, emphasizing risk assessments and validated testing methods.  

With increasing regulatory focus on elemental impurity control, manufacturers must establish a robust testing strategy to ensure compliance. Two primary techniques for elemental impurity testing are:

  • Inductively Coupled Plasma Mass Spectrometry (ICP-MS)  
  • and Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES).  
In this article, we will explore the regulatory expectations for impurity testing, compare the strengths and limitations of ICP-MS and ICP-OES, and provide guidance on selecting the best method for your needs.  
 
Each method has unique advantages, making the selection process dependent on specific testing needs. 

Regulatory expectations and testing requirements 

The ICH Q3D guideline mandates that a control strategy must be implemented if a risk assessment identifies an elemental impurity exceeding 30% of the Permitted Daily Exposure (PDE) limit. In many cases, this requires elemental impurity testing using validated methods. 

To comply with ICH Q3D, manufacturers can use pharmacopoeial methods or validated alternative procedures. The two most common techniques are ICP-MS and ICP-OES, each with specific applications based on sensitivity, cost, and regulatory needs. 

ICP-MS analysis: high sensitivity for trace-level detection 

ICP-MS is widely regarded as the gold standard for elemental impurity analysis due to its ultra-low detection limits, often in the parts-per-trillion (ppt) range 

This makes it ideal for detecting toxic metals such as:

  • Arsenic (As)
  • Cadmium (Cd)
  • Mercury (Hg)
  • Lead (Pb) 

Advantages of ICP-MS analysis

ICP-MS offers several benefits that make it the preferred choice for detecting trace-level elemental impurities, particularly in pharmaceutical applications: 

Ultra-low detection limits – Ensures compliance with strict impurity thresholds.  

High specificity – Can differentiate between isotopes of the same element.  

Broad elemental range – Detects a wide spectrum of elements in a single analysis. 


However,
ICP-MS has limitations, including:

  • Matrix interferences – Sample preparation and correction techniques are required.
  • Higher costs – More expensive instrumentation and maintenance compared to ICP-OES. 
 

 

ICP-OES analysis: robust and cost-effective for higher concentrations

ICP-OES, also known as ICP-AES (Atomic Emission Spectroscopy), measures elemental concentrations by analyzing the light emitted from excited atoms in a plasma.  

While not as sensitive as ICP-MS, it is highly effective for higher concentration ranges (parts-per-billion (ppb) to parts-per-million (ppm)) and is commonly used for routine quality control testing. 

Advantages of ICP-OES analysis

For applications where higher detection limits are acceptable, ICP-OES provides a cost-effective and efficient solution with several key advantages: 

Cost-effective – Lower operational and maintenance costs compared to ICP-MS.  

High throughput – Faster analysis times make it ideal for large sample batches.  

Resistant to matrix interferences – More robust when handling complex sample compositions.

ICP-OES is an excellent choice when ppt-level detection is not required, making it ideal for applications such as:

  • Excipient testing
  • Raw material screening
  • Heavy metal analysis at moderate concentrations 

 

ICP-MS vs ICP-OES: which technique should you choose? 

Choosing between ICP-MS and ICP-OES depends on several key factors: 

Factor 

ICP-MS 

ICP-OES 

Regulatory compliance 

Required for ultra-low detection limits 

Suitable for less stringent impurity thresholds 

Elemental concentration 

Best for trace-level detection 

Ideal for higher concentration samples 

Sample matrix complexity 

Requires careful interference correction 

More resistant to matrix effects 

Cost 

Higher initial and operational costs 

More cost-effective for routine testing 


In short:

  • Choose ICP-MS if ultra-low detection limits are required.
  • Choose ICP-OES for cost-effective routine analyses where ppt-level detection is unnecessary.

How QbD Group can support your testing needs 

At Quercus, part of QbD Group, we offer comprehensive elemental impurity testing using both ICP-MS and ICP-OES. Our experts provide: 

ICH Q3D-compliant testing  
Method validation and routine analysis  
Customized risk assessment strategies 

Partnering with an accredited contract laboratory ensures reliable data and streamlined compliance.  

Contact us today to learn more about our elemental impurity testing services and ensure regulatory readiness! 

 

Stay ahead in life sciences

Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

Circles-banner-short

Discover more expert content

preview_image
Whitepaper

ICH Stability Studies on Pharmaceuticals

This whitepaper discusses the importance of different methods for testing the stability of pharmaceutical products, stability study guidelines, and other aspects related to the stability of pharmaceutical products.
preview_image
Whitepaper

EU GMP: How to import your products into the EU?

Are you a medicinal product manufacturer looking to import your products into the EU in line with the latest EU-GMP import regulations? Download our guide.
preview_image
Whitepaper

Organic and mutagenic impurities in pharma

Ensure pharmaceutical quality and safety by controlling organic and mutagenic impurities. Download this whitepaper to learn more.
preview_image
Blog

Establishing and Maintaining the Right Level of Clinical Evidence under the EU IVDR

We’re proud to highlight a new publication by Pieter Bogaert, PhD—senior...
preview_image
Blog

Post-Market Surveillance (PMS) and Post-Market Clinical Follow-Up (PMCF) under the MDR: Ensuring safety and performance

With the introduction of the Medical Device Regulation (MDR), the...
preview_image
Blog

What Makes Usability Testing Crucial for Near-Patient and Self-Testing Devices under IVDR?

It shouldn’t be a surprise that today, “Near-Patient Testing (NPT)” and...
preview_image
Blog

When does Annex XIV apply in Performance Studies, and what key documentation is needed for compliance?

In the European regulatory landscape, conducting performance studies for in...